Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes

Reche, Pedro A; Keskin, Derin B; Hussey, Rebecca E; Ancuta, Petronela; Gabuzda, Dana; Reinherz, Ellis L

doi:10.1186/1476-9433-5-1

Medical Immunology

Table 4 HIV-1 patient information and CTL responses to peptide pools

From: Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes

	PATIENT INFORMATION							CTL RESPONSES TO PEPTIDE POOLS AS DETERMINED BY INTERFERON-GAMMA ELISPOT (SFC*)
PATIEND ID	HLA TYPE	DISEASE STAGE*	HAART*	ON HAART SINCE	INFECTED SINCE	VL*	PBMC DATE*	Pool 1	Pool 1	Pool 2	Pool 2	Pool 3	Pool 3	Pool 4	Pool 4	Pool 5	Pool 5	CEF*	NEG	NEG	NEG	POS
1	Unavailable	Unavailable	Unavailable	NA	Unavailable	Unavailable	6/22/04	1860	1610	530	510	700	620	10	10	10	10	0	0	0	0	PPP
2	Unavailable	Unavailable	Unavailable	NA	Unavailable	Unavailable	2/17/04	910	960	20	0	40	40	0	0	10	10	0	20	0	0	PPP
3	Unavailable	Chronic	No	NA	Unknown	>750000	2/19/04	0	0	0	10	0	0	0	0	0	0	675	0	0	0	PP
4	Unavailable	Chronic	No	NA	Unknown	>750000	2/26/04	0	0	0	0	0	0	0	0	0	0	70	0	0	0	PPP
5	Unavailable	Chronic	No	NA	Unknown	12905	3/4/04	110	150	60	80	90	70	50	30	30	40	266	60	40	50	PPP
6	Unavailable	Chronic	Yes	4/18/01	Unknown	176	2/26/04	180	130	150	200	150	150	210	250	100	120	163	0	0	0	PPP
7	Unavailable	Chronic	Yes	1/26/03	Unknown	6030	2/19/04	0	0	0	0	0	0	0	0	0	10	60	0	0	0	PPP
8	Unavailable	Chronic	Yes	NA	Unknown	>750000	2/24/04	0	0	0	0	0	0	0	0	0	0	>1000	0	0	0	PPP
9	Unavailable	Chronic	No	NA	Unknown	>500000	2/19/04	0	0	10	0	30	20	170	150	0	0	540	0	0	0	PP
10	Unavailable	Chronic	No	NA	Unknown	35100	2/26/04	1440	1010	1010	760	1040	1070	1050	1080	1270	1160	>1000	10	20	40	PPP
11	Unavailable	Chronic	No	NA	Unknown	236000	3/2/04	10	10	30	30	20	20	30	30	30	40	20	10	30	10	PPP
12	Unavailable	Chronic	No	NA	Unknown	9030	2/19/04	0	0	0	0	0	0	0	0	0	0	140	0	0	0	PP
13	Unavailable	Chronic	No	NA	Unknown	12000	3/4/04	260	210	190	160	180	210	150	210	150	160	>1000	10	20	0	PPP
14	A11/74, B35/44, C4/5	Chronic	No	NA	Unknown	74	4/20/04	0	0	0	0	0	0	0	0	0	0	833	0	0	0	PPP
15	A30/33, B13/14, C5/8	Chronic	No	NA	Unknown	122	4/20/04	60	90	20	0	20	10	20	10	20	20	0	0	10	10	PPP
16	A25/32, B18/40, C2/12	Chronic	No	NA	Unknown	12700	4/20/04	420	410	340	350	220	370	550	490	620	500	0	10	10	0	PPP
17	a2/30, b44/57, c5/18	Chronic	No	NA	Unknown	49	4/27/04	380	380	420	470	330	410	490	500	360	250	953	0	0	0	PPP
18	A1/74, B57/81, C7/18	Chronic	No	NA	Unknown	845	6/3/04	0	20	0	20	10	10	10	0	20	20 ND	0	0		10	PP
19	A3/33, B15/49, C7/14	Chronic	No	NA	Unknown	49	6/16/04	350	350	170	140	230	270	220	240	110	90 ND	0	0		10	PPP
20	A29, B44, C16	Chronic	No	NA	Unknown	807	6/16/04	210	180	130	180	200	260	0	20	0	0 ND	0	10		0	PPP
21	A1/24, B13/57, C6	Acute	No	NA	Unknown	5490	6/22/04	130	120	110	120	270	230	0	0	0	0	60	0	10	0	PPP
22	A1/24, B8/35, C4/7	Acute	Yes	7/21/03	2002, May	<50	2/17/04	130	100	30	50	70	40	120	100	70	50	347	0	0	0	PPP
23	A24/32, B35/41, C4/17	Acute	Yes	6/1/02	2002, Jun	<50	2/19/04	0	0	0	0	0	0	260	300	200	140	146	0	0	10	PPP
24	A2/31, B40/44, C3/16	Acute	Yes	9/2/03	2003, Aug	<400	2/26/04	0	0	0	0	0	0	0	0	0	0	440	0	0	0	PPP
25	A11/30, B15/35, C3/4	Acute	Yes	12/30/03	2003, Dec	<400	2/26/04	20	30	10	30	20	30	30	40	10	30	396	20	0	20	PPP
26	A11/24, B35/38, C4/7	Acute	Yes	5/19/99	1999, may	<50	3/1/04	0	0	0	0	0	0	0	0	0	0	60	0	20	0	PPP
27	A1/24, B14/35, C4/8	Acute	Yes	9/8/03	2003, JUL	<400	3/1/04	40	50	40	30	30	60	10	50	30	10	100	0	0	20	PPP
28	A1/11, B18/52, C12	Acute	Yes	8/25/99	1999, SEP	<50	3/9/04	0	0	0	0	0	0	0	0	0	0	520	0	0	0	PPP
29	A3/68, B14/44, B8/16	Acute	Yes	9/2/03	2003, AUG	<50	3/9/04	250	320	50	50	40	20	0	0	20	20	140	0	0	0	PPP
30	A1/32, B7/44, C7/16	Acute	Yes	2/18/04	2004, FEB	5,440	4/20/04	40	20	100	90	120	110	170	120	180	220	433	0	0	0	PPP
31	A2/3, B7/44, C5/7	Acute	Yes	8/1/97	1997-AUG	149	4/20/04	20	0	0	0	0	0	10	0	0	0	443	0	10	0	PP
32	A33, B53, C4	Acute	Yes	12/14/00	2000-NOV	<50	4/22/04	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PPP
33	A1/68, B7/8, C7/7	Acute	Yes	4/23/04	2004-APR	853	5/6/04	10	10	0	0	0	0	0	10	0	0	ND	0	0	0	PPP
34	A3/24, B40/57, C3/7	Acute	Yes	11/5/03	2003-NOV	<50	5/12/04	220	170	190	170	190	120	10	30	0	10	0	30	10	20	PPP
35	A26/68, B44/71, C3/7	Acute	Yes	12/22/98	1996-NOV	<50	5/13/04	0	0	0	20	10	10	0	10	10	10	20	10	10	10	PPP
36	A2/26, B53/57, C4/18	Acute	Yes	5/24/01	2001, MAY	<400	6/23/04	0	0	0	0	0	10	0	0	0	0	0	0	10	0	PPP
37	A2/74, B51/53, C4/14	Acute	Yes	8/22/01	2001, AUG	<50	6/22/04	0	10	0	10	20	20	0	20	0	10	986	0	0	0	PPP
38	A1/2, B8/15, C3/7	Acute	Yes	3/9/99	1999, MAR	1,111	5/19/04	420	430	480	420	500	410	430	410	430	480	326	0	0	0	PPP
39	A1/2, B7/8, C7/7	Acute	No	7/22/02	2002, JUL	<400	3/2/04	10	20	10	10	0	10	10	0	0	10	>1000	0	0	10	PPP
40	A23/24, B44/60, C3/14	Acute	No	NA	2004, FEB	1,580	3/15/04	210	220	90	90	80	100	0	0	0	0	70	0	20	0	PPP
41	A1/3, B8/15, C7	Acute	No	NA	2003, AUG	56,100	4/14/04	260	210	380	480	360	290	300	430	430	440	ND	0	0	0	PPP
42	A2/31, B15/51, C3/15	Acute	No	NA	2003-MAY	2,620	6/3/04	410	430	480	410	490	430	440	410	400	470	116	0	0	20	PPP
43	A3/24, B14/35, C8/12	Acute	No	NA	2000-MAY	883	5/26/04	250	250	40	30	20	40	40	40	40	30	80	0	0	10	PPP
44	A1/3, B35/40, C4/15	Acute	No	NA	2003-OCT	121,000	5/13/04	910	1150	1010	1010	1100	1080	980	1330	930	1090	260	0	0	0	PPP
45	A3/41, B14/35, C8/12	Acute	No	NA	2002, FEB	29,000	6/22/04	950	1090	30	40	40	60	40	40	50	60	143	0	0	0	PPP
46	A2/32, B15/39, C4/15	Acute	No	NA	2001, OCT	48,000	6/23/04	1200	1200	1150	1460	1660	1300	1460	1290	1390	1540	160	0	10	10	PPP
47	A3/68, B35/44, C4/7	Acute	No	NA	1999, AUG	667	5/26/04	10	30	0	30	10	20	0	20	10	0	ND	0	20	10	PPP

CTL responses were determined by the interferon-gamma elispot assay
SFC*: Spot Forming Colonies
DISEASE STAGE*: refers to the stage at the time of diagnosis
HAART*: Patients were receiving HAART treatment at the time of PBMC collection
VL*: Viral Load at the time of PBMC sampling in copies/ml
PBMC DATE*: Date PBMC samples were collected
CEF: Response to CMV, EBV and Influenza A peptide pools.
POS is a PHA response where PP = high and PPP = highest responses related to non-stimulated controls. Both PP and PPP are equivalent to responses form normal individuals.
NA, Not Applicable

Back to article page